Research Papers:
DHHC3 interferes with antitumor immunity in melanoma cells
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 61 views | Full Text 126 views
Chandan Sharma1, Soonyean Hwang2, Qingshi Liu3 and Martin E. Hemler1
1 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2 Current address: UCB, 87 Cambridge Park Dr, Cambridge, MA 02140, USA
3 Current address: Chinese Institutes for Medical Research, Beijing 100069, China
Correspondence to:
| Martin E. Hemler, | email: | [email protected] |
| Chandan Sharma, | email: | [email protected] |
Keywords: oxidative stress; DHHC3; anti-cancer immunity; palmitoylation; melanoma
Received: August 18, 2025 Accepted: April 30, 2026 Published: June 08, 2026
ABSTRACT
The protein-acyltransferase DHHC3 supports a few different tumor malignancies, but mechanisms have been unclear. Here we report that DHHC3-null B16F10 melanoma cells showed markedly elevated oxidative stress and senescence, accompanied by diminished tumor growth within immunocompetent C57/BL6 mice, but not in immunodeficient NOD-SCID mice. These results suggest that absence of DHHC3 enhances innate and/or adaptive anti-melanoma immunity. Consistent with this, DHHC3-null melanomas contained elevated numbers of anti-tumor cells (M1 macrophages, NK, CD4+T, CD8+T), whereas pro-tumor cells (M2 macrophages, MDSCs) were diminished. Unexpectedly, DHHC3 ablation minimally affected experimental metastasis of cells injected into either immunocompetent C57/BL6 or immunodeficient NOD-SCID mice. We conclude that DHHC3 ablation does not fundamentally alter melanoma cell growth and invasion/metastasis (independent of the immune system) despite its effects on oxidative stress and senescence. However, DHHC3 does control primary melanoma growth by supporting anti-melanoma immunity.